Top-Rated StocksTop-RatedNASDAQ:LEGN Legend Biotech (LEGN) Stock Price, News & Analysis $56.61 -2.53 (-4.28%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$55.93▼$59.4050-Day Range$39.50▼$59.8852-Week Range$38.60▼$77.30Volume979,058 shsAverage Volume1.10 million shsMarket Capitalization$10.32 billionP/E RatioN/ADividend YieldN/APrice Target$81.31 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Legend Biotech alerts: Email Address Legend Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside43.6% Upside$81.31 Price TargetShort InterestBearish6.07% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.59Based on 13 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.94) to ($0.54) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.11 out of 5 starsMedical Sector388th out of 936 stocksPharmaceutical Preparations Industry184th out of 436 stocks 4.5 Analyst's Opinion Consensus RatingLegend Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 14 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLegend Biotech has been the subject of 8 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Legend Biotech's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted6.07% of the outstanding shares of Legend Biotech have been sold short.Short Interest Ratio / Days to CoverLegend Biotech has a short interest ratio ("days to cover") of 9.1.Change versus previous monthShort interest in Legend Biotech has recently decreased by 0.90%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldLegend Biotech does not currently pay a dividend.Dividend GrowthLegend Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LEGN. Previous Next 2.6 News and Social Media Coverage News SentimentLegend Biotech has a news sentiment score of 0.59. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Legend Biotech this week, compared to 4 articles on an average week.Search Interest7 people have searched for LEGN on MarketBeat in the last 30 days. This is an increase of 17% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Legend Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Legend Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.02% of the stock of Legend Biotech is held by insiders.Percentage Held by Institutions70.89% of the stock of Legend Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Legend Biotech's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Legend Biotech are expected to grow in the coming year, from ($1.94) to ($0.54) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Legend Biotech is -43.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Legend Biotech is -43.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLegend Biotech has a P/B Ratio of 8.23. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Legend Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About Legend Biotech Stock (NASDAQ:LEGN)Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.Read More LEGN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LEGN Stock News HeadlinesJuly 15, 2024 | marketbeat.comCPI Data Sparks Rally in Biotech Stocks (LEGN)Following lower-than-expected inflation data on Thursday, The biotech sector broke out above resistance, closing the week up 6%, far outperforming the market.July 26 at 7:00 AM | globenewswire.comLegend Biotech Announces Preliminary Results for the Six-Months Ended June 30, 2024July 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…July 22, 2024 | americanbankingnews.comLegend Biotech Co. (NASDAQ:LEGN) Forecasted to Earn Q2 2024 Earnings of ($0.34) Per ShareJuly 20, 2024 | americanbankingnews.comLegend Biotech (NASDAQ:LEGN) Stock Rating Reaffirmed by HC WainwrightJuly 20, 2024 | americanbankingnews.comScotiabank Increases Legend Biotech (NASDAQ:LEGN) Price Target to $70.00July 19, 2024 | americanbankingnews.comHC Wainwright Brokers Reduce Earnings Estimates for Legend Biotech Co. (NASDAQ:LEGN)July 18, 2024 | americanbankingnews.comLegend Biotech Co. (NASDAQ:LEGN) Receives Consensus Rating of "Buy" from BrokeragesJuly 26, 2024 | DTI (Ad)How a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…July 10, 2024 | globenewswire.comLegend Biotech to Host Investor Conference Call on Second Quarter 2024 ResultsJune 17, 2024 | benzinga.comLegend Biotech's Cancer Drug, 'The Most Attractive Product,' Set For Growth: AnalystJune 3, 2024 | businesswire.comLegend Biotech Shares Data on the Earliest Use to Date of CARVYKTI® in the Treatment of Multiple Myeloma and Important Subgroup Analyses at ASCO and EHAMay 29, 2024 | businesswire.comLegend Biotech to Participate in the Jefferies Global Healthcare ConferenceMay 26, 2024 | uk.investing.comLegend Biotech stock PT cut by H.C. Wainwright amid revenue slowdownMay 24, 2024 | msn.comDeutsche Bank Initiates Coverage of Legend Biotech Corporation - Depositary Receipt () (LEGN) with Buy RecommendationMay 23, 2024 | businesswire.comLegend Biotech to Highlight Leadership in CAR-T Cell Therapy for Patients with Multiple Myeloma at ASCO and EHAMay 22, 2024 | finanznachrichten.deMaxCyte, Inc: MaxCyte Signs Strategic Platform License Agreement with Legend Biotech to Accelerate Cell Therapy Discovery and DevelopmentMay 15, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Daré Bioscience (DARE), Legend Biotech (LEGN) and Singular Genomics Systems (OMIC)See More Headlines Receive LEGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Legend Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/13/2024Today7/26/2024Next Earnings (Confirmed)8/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LEGN CUSIPN/A CIK1801198 Webwww.legendbiotech.com Phone732-317-5050FaxN/AEmployees1,800Year FoundedN/APrice Target and Rating Average Stock Price Target$81.31 High Stock Price Target$94.00 Low Stock Price Target$60.00 Potential Upside/Downside+43.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($1.30) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-518,250,000.00 Net Margins-135.92% Pretax Margin-182.41% Return on Equity-27.91% Return on Assets-19.49% Debt Debt-to-Equity Ratio0.25 Current Ratio5.66 Quick Ratio5.57 Sales & Book Value Annual Sales$342.80 million Price / Sales30.10 Cash FlowN/A Price / Cash FlowN/A Book Value$6.88 per share Price / Book8.23Miscellaneous Outstanding Shares182,283,000Free Float182,247,000Market Cap$10.32 billion OptionableOptionable Beta0.11 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesDr. Ying Huang Ph.D. (Age 51)CEO & Director Ms. Lori A. Macomber CPA (Age 53)Chief Financial Officer Mr. Doug WallaceVice President of Global OperationsDr. Guowei Fang Ph.D.Chief Scientific Officer & Head of Business DevelopmentJoanne ChoiSenior Manager of Investor RelationsMr. James Pepin J.D.General CounselDeborah WongExecutive Director of Strategic Marketing & Corporate CommunicationsMs. Elaine QianVP & Global Head of Human ResourcesDr. Yuhong Qiu Ph.D.Senior Vice President of Global Regulatory AffairsMr. Steven J. GavelSenior Vice President of Commercial Development, US & EuropeMore ExecutivesKey CompetitorsEidos TherapeuticsNASDAQ:EIDXPrincipia BiopharmaNASDAQ:PRNBAutolus TherapeuticsNASDAQ:AUTLbluebird bioNASDAQ:BLUETakeda PharmaceuticalNYSE:TAKView All CompetitorsInstitutional OwnershipBank of New York Mellon CorpBought 17,162 shares on 7/26/2024Ownership: 0.060%EFG Asset Management North America Corp.Bought 1,820 shares on 7/26/2024Ownership: 0.039%China Universal Asset Management Co. Ltd.Sold 5,695 shares on 7/20/2024Ownership: 0.005%Sumitomo Mitsui Trust Holdings Inc.Sold 2,018 shares on 7/19/2024Ownership: 0.089%Blue Trust Inc.Bought 806 shares on 7/18/2024Ownership: 0.000%View All Institutional Transactions LEGN Stock Analysis - Frequently Asked Questions How have LEGN shares performed this year? Legend Biotech's stock was trading at $60.17 at the beginning of the year. Since then, LEGN stock has decreased by 5.9% and is now trading at $56.61. View the best growth stocks for 2024 here. How were Legend Biotech's earnings last quarter? Legend Biotech Co. (NASDAQ:LEGN) announced its quarterly earnings results on Monday, May, 13th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.13. The firm's quarterly revenue was up 158.7% compared to the same quarter last year. When did Legend Biotech IPO? Legend Biotech (LEGN) raised $350 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 18,400,000 shares at $18.00-$20.00 per share. Morgan Stanley, J.P. Morgan Securities and Jefferies served as the underwriters for the IPO. Who are Legend Biotech's major shareholders? Legend Biotech's top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.09%), Bank of New York Mellon Corp (0.06%), EFG Asset Management North America Corp. (0.04%) and E Fund Management Hong Kong Co. Ltd. (0.03%). How do I buy shares of Legend Biotech? Shares of LEGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Legend Biotech own? Based on aggregate information from My MarketBeat watchlists, some other companies that Legend Biotech investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), CrowdStrike (CRWD), Lam Research (LRCX), ServiceNow (NOW), Peloton Interactive (PTON) and QUALCOMM (QCOM). This page (NASDAQ:LEGN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Legend Biotech Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Legend Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
